Literature DB >> 1489191

Pharmacokinetics of a clarithromycin suspension in infants and children.

V N Gan1, S Y Chu, H T Kusmiesz, J C Craft.   

Abstract

The single- and multiple-dose pharmacokinetics of clarithromycin and its 14-(R)-hydroxylated metabolite in infants and children were studied after oral administration under fasting and nonfasting conditions. Drug absorption appeared to be rapid following a brief delay in its onset; the mean peak concentrations in plasma (Cmax) for clarithromycin were reached within about 3 h under both conditions. The mean Cmax for the parent drug were 3.59 and 4.58 micrograms/ml in single-dose fasting and nonfasting patients, and the respective Cmax for the metabolite were 1.19 and 1.26 micrograms/ml. Data indicate good absorption and no significant effects by food. There was no unusual accumulation in the area under the concentration-time curve and Cmax in the multiple-dose group.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1489191      PMCID: PMC284357          DOI: 10.1128/AAC.36.11.2478

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

Review 1.  New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  Simultaneous determination of clarithromycin and 14(R)-hydroxyclarithromycin in plasma and urine using high-performance liquid chromatography with electrochemical detection.

Authors:  S Y Chu; L T Sennello; R C Sonders
Journal:  J Chromatogr       Date:  1991-11-15

3.  Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.

Authors:  D J Hardy; R N Swanson; R A Rode; K Marsh; N L Shipkowitz; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

4.  Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria.

Authors:  N X Chin; N M Neu; P Labthavikul; G Saha; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

5.  The development of macrolides: clarithromycin in perspective.

Authors:  H C Neu
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

Review 6.  New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

  6 in total
  10 in total

Review 1.  Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.

Authors:  H D Langtry; R N Brogden
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of clarithromycin.

Authors:  K A Rodvold
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 3.  Macrolide antibiotics in paediatric infectious diseases.

Authors:  D R Guay
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 4.  Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.

Authors:  J Singh; B Burr; D Stringham; A Arrieta
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

5.  In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetti to clarithromycin.

Authors:  M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

Review 6.  Clarithromycin. A review of its pharmacological properties and therapeutic use in Mycobacterium avium-intracellulare complex infection in patients with acquired immune deficiency syndrome.

Authors:  L B Barradell; G L Plosker; D McTavish
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

7.  A comparative study of clarithromycin and amoxycillin suspensions in the treatment of pediatric patients with acute otitis media.

Authors:  S J Coles; M B Addlestone; M K Kamdar; J L Macklin
Journal:  Infection       Date:  1993 Jul-Aug       Impact factor: 3.553

Review 8.  Clarithromycin clinical pharmacokinetics.

Authors:  F Fraschini; F Scaglione; G Demartini
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

9.  Long-term and per rectum disposition of Clarithromycin in the desert tortoise (Gopherus agassizii).

Authors:  Jeffrey Wimsatt; Alysa Tothill; Cord F Offermann; Jenifer G Sheehy; Charles A Peloquin
Journal:  J Am Assoc Lab Anim Sci       Date:  2008-07       Impact factor: 1.232

10.  On the Design of Food Effect Studies in Adults for Extrapolating Oral Drug Absorption Data to Infants: an Exploratory Study Highlighting the Importance of Infant Food.

Authors:  Marina Statelova; Konstantinos Goumas; Nikoletta Fotaki; René Holm; Mira Symillides; Christos Reppas; Maria Vertzoni
Journal:  AAPS J       Date:  2019-12-02       Impact factor: 4.009

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.